Back to results
US 11,446,369 B2Granted
Compositions and methods comprising KLK3 or FOLH1 antigen
AssigneesAdvaxis, Inc., The Trustees of the University of Pennsylvania
InventorsYvonne Paterson, John Rothman, Vafa Shahabi
Life of this patent
Estimating the term…
Abstract
The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
Claims16
A method of inhibiting prostate cancer metastasis in a subject, comprising:
- administering to the subject a composition comprising a recombinant Listeria strain encoding a recombinant fusion peptide consisting of a KLK3 peptide operatively linked to a non-KLK3 peptide, wherein the non-KLK3 peptide is a N-terminal non-hemolytic listeriolysin (LLO) peptide, the fusion peptide consisting of the sequence of SEQ ID NO:
- 54 or a sequence at least 99% homologous (throughout the length of the peptide), wherein the metastasis is inhibited.
A method of treating prostate cancer metastasis in a subject, comprising:
- administering to the subject a composition comprising a recombinant Listeria strain encoding a recombinant fusion peptide consisting of a KLK3 peptide operatively linked to a non-KLK3 peptide, wherein the non-KLK3 peptide is a N-terminal non-hemolytic listeriolysin (LLO) peptide, the fusion peptide consisting of the sequence of SEQ ID NO:
- 54 or a sequence at least 99% homologous (throughout the length of the peptide), wherein the subject has metastatic prostate cancer.
Dependencies are inferred from the claim text.